<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161664</url>
  </required_header>
  <id_info>
    <org_study_id>M19CVT</org_study_id>
    <nct_id>NCT04161664</nct_id>
  </id_info>
  <brief_title>Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy</brief_title>
  <acronym>CRAVAT</acronym>
  <official_title>Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy (CRAVAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes
      invalidating and chronic postoperative morbidity, especially in patients with high stage
      disease. Theoretically, downstaging with neo adjuvant chemotherapy could shrink the tumour,
      making surgical treatment less extensive thereby diminishing the chance for morbidity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes
      invalidating and chronic postoperative morbidity, especially in patients with high stage
      disease. Theoretically, downstaging with neo adjuvant chemotherapy could shrink the tumour,
      making surgical treatment less extensive thereby diminishing the chance for morbidity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>a prospective, phase II trial to investigate the response rate of carboplatin and paclitaxel in patients with vulvar carcinoma</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumour size reduction by neo adjuvant chemotherapy</measure>
    <time_frame>18 weeks</time_frame>
    <description>tumour size reduction measured by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chemotherapy related morbidity</measure>
    <time_frame>21 weeks</time_frame>
    <description>chemotherapy related morbidity measured by number and grade of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years after treatment</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Metastatic Squamous Cell Carcinoma of the Vulva</condition>
  <arm_group>
    <arm_group_label>neo adjuvant Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and Carboplatin</intervention_name>
    <description>6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule</description>
    <arm_group_label>neo adjuvant Paclitaxel and Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman 18 years

          -  Signed and written informed consent.

          -  Histologically confirmed squamous cell vulvar carcinoma

          -  World Health Organization performance status of 0-2

          -  Adequate hematological function

          -  Adequate hepatic function

          -  Adequate renal function

          -  Negative pregnancy test for woman of childbearing potential

          -  Histologically or CT scan confirmed metastatic squamous cell vulvar carcinoma

          -  Measurable disease

          -  Lesion previously not irradiated

          -  TNM stage any T any N M1

        Exclusion Criteria:

          -  Vulvar cancer other than squamous cell carcinoma at biopsy

          -  Previous radiotherapy of the vulva, groins or pelvis

          -  Patients with metastasis limited to the pelvic lymph nodes, who can be primarily
             operated with curative intent

          -  Other diagnosis of malignancy or evidence of other malignancy for 5 years before
             screening for this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>vulva carcinoma</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Amant, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic Amant, MD, PhD</last_name>
    <phone>0031205129111</phone>
    <email>f.amant@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NKI-AVL Zijlmans, MD, PhD</last_name>
      <phone>0031205129111</phone>
      <email>h.zijlmans@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Henry Zijlmans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

